Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Anixa Biosciences announced that Jose Conejo-Garcia, MD, PhD, inventor of its ovarian cancer CAR-T therapy, will deliver a keynote at the 2026 Ovarian Cancer Midwest Focus Conference on November 3 in Rochester, Minnesota. The conference is hosted by Mayo Clinic and University of Minnesota; Conejo-Garcia is a Professor of Immunology at Duke University School of Medicine.
Key figures
- Drug Name
- liraltagene autoleucel (lira-cel)
- Phase Of Trial
- Phase 1
- Stable disease duration days
- 90
- Patients surviving over one year
- 4
- Dose limiting toxicities observed
- 0
- Patients surviving beyond two years
- 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.